We thank Dr Akio Hara and Prof. Takashi Yoshioka and colleagues for their interest and comments on our study investigating the association between high-intensity statins and clinical outcome in malignant pleural mesothelioma (MPM) and advanced non–small cell lung cancer (aNSCLC) patients treated with programmed cell death protein 1 (PD-1) inhibitors [
- Cantini L.
- Pecci F.
- Hurkmans D.P.
- Belderbos R.A.
- Lanese A.
- Copparoni C.
- et al.
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
Eur J Canc. 2021; 144https://doi.org/10.1016/j.ejca.2020.10.031
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.Eur J Canc. 2021; 144https://doi.org/10.1016/j.ejca.2020.10.031
- Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program.Transl Lung Cancer Res. 2020; (0): 1169-1179https://doi.org/10.21037/tlcr-19-686
- Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%.Cancer Immunol Immunother. 2020; https://doi.org/10.1007/s00262-020-02613-9
- Confounding: what it is and how to deal with it.Kidney Int. 2008; 73: 256-260https://doi.org/10.1038/sj.ki.5002650
- Lipid signalling enforces functional specialization of Treg cells in tumours.Nature. 2021; 591: 306-311https://doi.org/10.1038/s41586-021-03235-6
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.Nat Immunol. 2020; 21: 1346-1358https://doi.org/10.1038/s41590-020-0769-3
- The mevalonate pathway is a druggable target for vaccine adjuvant discovery.Cell. 2018; https://doi.org/10.1016/j.cell.2018.08.070
- Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate.Nat Commun. 2020; 11: 1-12https://doi.org/10.1038/s41467-020-17179-4
Published online: June 18, 2021
Accepted: May 8, 2021
Received in revised form: April 28, 2021
Received: April 10, 2021
© 2021 Elsevier Ltd. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patientsEuropean Journal of CancerVol. 144
- Re: ‘High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients’European Journal of CancerVol. 153
- PreviewWe carefully read the article by Cantini et al. . This is an interesting study that evaluated the association between statin use and clinical outcomes of programmed cell death 1 (PD-1) use using a prospective database. If statins improve clinical outcomes in patients treated with PD-1 inhibitors, treatment strategies for malignant pleural mesothelioma (MPM) and advanced non-small cell lung cancer (aNSCLC) will dramatically change. Furthermore, this study suggests that those who do not take statins may have a worse overall survival after the use of PD-1 inhibitors for both MPM and aNSCLC, highlighting the importance of pre-treatment cardiovascular risk assessment before treatment with PD-1 inhibitors.